{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:41:23Z","timestamp":1760060483424,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea (NRF)","doi-asserted-by":"publisher","award":["RS-2019-NR040070"],"award-info":[{"award-number":["RS-2019-NR040070"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Interleukin-33 (IL-33) is crucial in immune-mediated diseases like asthma. Targeting the IL-33\/ST2 pathway holds therapeutic promise. This study characterized the pharmacokinetics (PK) and metabolism of KB-1517 and KB-1518, new oxazolo[4,5-c]quinoline IL-33 inhibitors. Methods: PK studies were conducted in male ICR mice following intravenous (IV) and oral (PO) administration. In vitro metabolic stability and metabolite identification were assessed using human and mouse liver S9 fractions supplemented with cofactors (NADPH, UDPGA, PAPS, GSH). Plasma and incubation samples were analyzed using validated LC-MS\/MS methods. Results: KB-1517 exhibited slow absorption\/elimination and high apparent oral bioavailability (&gt;100%) post-PO, with an unusually late increase in plasma concentration after IV dosing, hindering terminal parameter calculation. KB-1518 showed low clearance post-IV but suffered from low oral bioavailability (~14%). Both compounds demonstrated high in vitro metabolic stability (t\u00bd &gt; 60 min) in both human and mouse liver S9 fractions. Primary metabolism involved phase I oxidation (N-oxidation and N-demethylation), yielding several metabolites identified in vitro and confirmed in vivo. Some species differences in metabolite profiles were observed. Conclusions: KB-1517 and KB-1518 are promising, metabolically stable IL-33 inhibitor lead compounds with distinct PK profiles. KB-1517\u2019s complex kinetics suggest potential sustained exposure but require further elucidation. KB-1518\u2019s low oral bioavailability necessitates further optimization. These ADME findings provide a critical foundation for their continued optimization and development.<\/jats:p>","DOI":"10.3390\/pharmaceutics17091153","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:04:15Z","timestamp":1756886655000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Metabolism and Pharmacokinetics of Oxazolo[4,5-c]quinoline Analogs as Novel Interleukin-33 Inhibitors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-0019","authenticated-orcid":false,"given":"Hayoung","family":"Jeon","sequence":"first","affiliation":[{"name":"College of Pharmacy, Korea University, Sejong 30019, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geonhee","family":"Jang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Korea University, Sejong 30019, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-A","family":"Ban","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Korea University, Sejong 30019, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyun","family":"Son","sequence":"additional","affiliation":[{"name":"Azcuris Co., Ltd., 2511 Sejong-ro, Sejong 30019, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-7734","authenticated-orcid":false,"given":"Youngjoo","family":"Byun","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Korea University, Sejong 30019, Republic of Korea"},{"name":"Interdisciplinary Major Program in Innovative Pharmaceutical Sciences, Korea University, Sejong 30019, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6151-6543","authenticated-orcid":false,"given":"Kiho","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Korea University, Sejong 30019, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"To, T., Stanojevic, S., Moores, G., Gershon, A.S., Bateman, E.D., Cruz, A.A., and Boulet, L.P. (2012). Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health, 12.","DOI":"10.1186\/1471-2458-12-204"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.130.1_suppl.4S","article-title":"The global burden of asthma","volume":"130","author":"Braman","year":"2006","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Comberiati, P., Di Cicco, M.E., D\u2019Elios, S., and Peroni, D.G. (2017). How much asthma is atopic in children?. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00122"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Martin-Orozco, E., Norte-Munoz, M., and Martinez-Garcia, J. (2017). Regulatory T cells in allergy and asthma. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00117"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/all.13320","article-title":"The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies","volume":"73","author":"Abuabara","year":"2018","journal-title":"Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-065X.2010.00951.x","article-title":"Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors","volume":"238","author":"Zhu","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nri2870","article-title":"Functions of T cells in asthma: More than just TH2 cells","volume":"10","author":"Lloyd","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","article-title":"IL-4 and IL-13 signaling in allergic airway disease","volume":"75","author":"Gour","year":"2015","journal-title":"Cytokine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/rr40","article-title":"Th2 cytokines and asthma. Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists","volume":"2","author":"Steinke","year":"2001","journal-title":"Respir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/07853890701449354","article-title":"Triggers of IgE class switching and allergy development","volume":"39","author":"Poulsen","year":"2007","journal-title":"Ann. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chan, B.C., Lam, C.W., Tam, L.S., and Wong, C.K. (2019). IL33: Roles in allergic inflammation and therapeutic perspectives. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00364"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/intimm\/dxn037","article-title":"Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system","volume":"20","author":"Kondo","year":"2008","journal-title":"Int. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Stolarski","year":"2009","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2009.12.935","article-title":"Increased IL-33 expression by epithelial cells in bronchial asthma","volume":"125","author":"Nadigel","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1542\/peds.109.SE1.381","article-title":"Balancing safety and efficacy in pediatric asthma management","volume":"109","author":"Skoner","year":"2002","journal-title":"Pediatrics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.rmed.2013.09.007","article-title":"Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes","volume":"107","author":"Aasbjerg","year":"2013","journal-title":"Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"676897","DOI":"10.1155\/2015\/676897","article-title":"Alternative, complementary, and forgotten remedies for atopic dermatitis","volume":"2015","author":"Goddard","year":"2015","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2500\/aap.2019.40.4277","article-title":"Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria","volume":"40","author":"Chiarella","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4155\/fmc.13.112","article-title":"Development of small molecules to target the IgE:Fc\u03b5RI protein-protein interaction in allergies","volume":"5","author":"Smith","year":"2013","journal-title":"Future Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e99208","DOI":"10.1172\/jci.insight.99208","article-title":"From proteomics to discovery of first-in-class ST2 inhibitors active in vivo","volume":"3","author":"Ramadan","year":"2018","journal-title":"JCI Insight"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/asia.202100896","article-title":"Rational design, synthesis and evaluation of oxazolo[4,5-c]quinolinone analogs as novel interleukin-33 inhibitors","volume":"16","author":"Kim","year":"2021","journal-title":"Chem. Asian J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jaci.2015.09.059","article-title":"IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3","volume":"137","author":"Desai","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.2018.212126","article-title":"Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production","volume":"105","author":"Tobio","year":"2020","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1242\/dmm.000323","article-title":"Mouse models of allergic asthma: Acute and chronic allergen challenge","volume":"1","author":"Nials","year":"2008","journal-title":"Dis. Model Mech."},{"key":"ref_30","first-page":"389","article-title":"Translational animal models of atopic dermatitis for preclinical studies","volume":"90","author":"Martel","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2125.2000.00296.x","article-title":"Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity","volume":"50","author":"Roots","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1124\/dmd.107.019646","article-title":"Role of Flavin-Containing Monooxygenase in oxidative metabolism of voriconazole by human liver microsomes","volume":"36","author":"Yanni","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","article-title":"Role of pharmacokinetics and metabolism in drug discovery and development","volume":"49","author":"Lin","year":"1997","journal-title":"Pharmacol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/tde.11.19","article-title":"Flip-flop pharmacokinetics\u2014Delivering a reversal of disposition:challenges and opportunities during drug development","volume":"2","author":"Yanez","year":"2011","journal-title":"Ther. Deliv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification\u2014The correlation of in-vitro drug product dissolution and in-vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:38:26Z","timestamp":1760035106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["pharmaceutics17091153"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17091153","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}